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Introduction: The significance of inorganic serum phosphate levels (Pi) in patients with
acute coronary syndromes (ACS) in the reperfusion era is unknown, as well as its relation
to biomarkers of myocardial necrosis. Our aim was to assess admission Pi and its
dynamics in patients admitted to the intensive cardiac care unit (ICCU), with emphasis
on patients with ST segment elevation myocardial infarction (STEMI).
Methods: We studied 192 patients admitted to the ICCU during a 4-month period. The first
group included 92 patients with STEMI (STEMI group) treated by primary percutaneous
coronary intervention (PCI). The second group consisted of 100 patients without ACS (non-
ACS group). Normophosphatemia was defined as Pi 0.7–1.6 mmol/l. Phosphatemia was
measured at admission and then 6 h and 12 h later as well as troponin I.
Results: Admission phosphatemia was lower in the STEMI group as compared to the non-
ACS group (Pi 0.95 mmol/l vs. 1.18 mmol/l, po0.001). Admission hypophosphatemia
(Pio0.7 mmol/l) was more often present in the STEMI group than in the non-ACS group
(21% vs. 4%, p¼0.001). In all hypophosphatemic STEMI patients, serum Pi normalized itself
within 6 h without substitution. Admission hyperphosphatemia (Pi41.6 mmol/l) was more
frequent in non-ACS group (6.5% STEMI pts. vs. 13% non-ACS pts.). In the STEMI group,
admission phosphatemia did not correlate with peak troponin I.
Conclusion: We conclude that patients with STEMI treated by primary PCI have lower Pi and
more frequent transient hypophosphatemia at admission than acute cardiac care patients
without acute coronary syndrome.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp. z.o.o. All
rights reserved.1. Background
Normal organ function and many metabolic processes are
dependent on intracellular aswell as on extracellular electrolyte
concentrations. Phosphorus is an essential element, majorityzech Society of Cardiolog
Lhotska´), pechman@fnp
fnplzen.cz (M. Hroma´dk(about 80%) is a part of bones and teeth. 9%, 11% and 0.1% is
found in skeletal muscle, viscera and extracellular fluid, respec-
tively [1]. Both organic and inorganic phosphate are present in
the blood. 85% of the inorganic form are free phosphate ions,
10% is bound with proteins and 5% with other minerals.y. Published by Elsevier Urban & Partner Sp.z.o.o. All rights
lzen.cz (V. Pechman), cechj@fnplzen.cz (J. Cˇech),
a), rokyta@fnplzen.cz (R. Rokyta Jr.).
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maintenance, cellular and subcellular metabolism (e.g. cellular
signal transduction, energy exchange) and in the cell structure
as a component of the cell membranes lipid bilayer. Most
intracellular phosphate is a component of creatine phosphate,
adenosine triphosphate (ATP, the store of biochemical energy)
and 2,3-diphosphoglycerate (2,3-DPG, the O2 release to tissue
from red cells). The most important regulator of the phosphate
plasma concentration are kidneys, the renal tubules reabsorb-
ing approximately 80–90% of the filtered phosphate.
Hypophosphatemia is usually categorized as moderate (Pi
0.3–0.7 mmol/l) or severe (Pio0.3 mmol/l). Moderate hypo-
phosphatemia occurs in 2.2–3.1% of hospitalized patients
[2–4], severe hypophosphatemia in 0.2–0.4% patients [2–6].
In intensive care unit patients, hypophosphatemia can be
caused by multiple factors, e.g. sepsis, trauma, fluid therapy,
etc. [1,2,7]. The most feared clinical consequences of severe
hypophosphatemia are rhabdomyolysis, hemolysis, leukocyte
dysfunction, perturbed nervous system, respiratory failure and
heart dysfunction [1,2,8,9]. Severe hypophosphatemia is typi-
cally present in alcoholics, septic patients, patients with mal-
nutrition and diabetic ketoacidosis and is associated with a
higher mortality rate [6,10].
Conversely, it has been shown that higher levels of serum
phosphate have an independent positive association with the
angiographic severity of coronary artery disease (CAD) and
with the risk of myocardial infarction or death in patients
with ischemic heart disease [11,12].
Data about the incidence and role of serum phosphorus
abnormalities in acute cardiac patients are scarce, in patients
with acute myocardial infarction mostly from the prereperfu-
sion era [13,14]. Our aim was to assess admission serum
inorganic phosphate (Pi) levels and its early dynamics in
patients admitted to the intensive cardiac care unit (ICCU), in
particular in patients with ST segment elevation myocardial
infarction (STEMI) as well as its potential relation to biomar-
kers of myocardial necrosis and other minerals.2. Methods
The study followed the principles established in the Declara-
tion of Helsinki. The protocol was approved by the local
ethics committee of University Hospital Plzen and all patientsTable 1 – Baseline characteristic.
STEMI group (
Age (years) 66 (711)
Males/Females 65/27 (71/29%
Hypertension 64 (70%)
Dyslipidemia 40 (43%)
Diabetes mellitus 25 (27%)
Smokers (incl. former smokers) 48 (56%)
PAOD 5 (5%)
Renal insufficiency (baseline creatinin4130 mmol/l) 30 (32%)
BMI 27.2 (73,8)
CAD 20 (22%)
Heart failure 7 (8%)
Data are number (%) or mean (7SD). STEMI¼patients with ST elevation
syndrome, PAOD¼peripheral artery occlusion disease, BMI¼body massprovided written informed consent. We prospectively evalu-
ated consecutive patients admitted to the ICCU during a
4-month period (at the end of the year 2008). The first group
included patients with acute myocardial infarction with ST
segment elevation (STEMI group) and the second group
comprised patients admitted to the ICCU without acute
coronary syndrome (non-ACS group). STEMI was diagnosed
in the presence of chest pain, diagnostic electrocardiographic
changes with characteristic ST segment elevation and ele-
vated troponin I level. All patients in the STEMI group
received standard antithrombotic therapy (clopidogrel, acet-
ylsalicylic acid, unfractioned heparin) before baseline labora-
tory, underwent urgent coronary angiography and were
treated by primary percutaneous coronary intervention (PCI).
Serum inorganic phosphate was measured using a stan-
dard photometric method (OSR 6122/6222, Beckman Coulter,
analyzer Olympus AU 640 or AU2700, Ireland) at the admis-
sion and then 6 h and 12 h later as well as cardiospecific
enzymes—troponin I, creatine kinase and myoglobin. Tropo-
nin I was measured using the AccuTnI Beckman method,
Reagent Catalog 33340 (Abbott, USA).
Normophosphatemia was defined as serum inorganic
phosphate level 0.7–1.6 mmol/l. Phosphorus and calcium
were administered neither parenterally nor enterally during
the study period.3. Statistical analysis
Data are meansþstandard deviation unless otherwise stated.
Statistical comparison of the groups was performed by the
Chi-Square test and Wilcoxon Rank Sum test. The po0.05
was considered as statistically significant. We compared
baseline characteristics of all patients. Then we compared
Pi at admission and at 6 h and 12 h afterwards in both groups.
In addition, we assessed the possible association of Pi with
peak troponin I levels as well as with admission levels of
calcium, potassium and magnesium.4. Results
Complete data were obtained in 192 patients (M/F 129/63,
mean age 66713 years). Acute myocardial infarction with ST92 pts.) Non-ACS group (100 pts.) Statistical significance
66 (714) ns
) 64/36 (64/36%) ns
66 (66%) ns
43 (43%) ns
31 (31%) ns
45 (45%) ns
9 (9%) ns
33 (33%) ns
28.0 (76,4) ns
35 (35%) 0.04
22 (22%) 0.01
myocardial infarction, non-ACS¼patients without acute coronary
index, CAD¼coronary artery disease.
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elevation;   p < 0,05 (difference vs. baseline); n = number of patients.  
Fig. 3 – Time course of Pi in STEMI with admission
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 3 2 – e 2 3 6e234segment elevation as the primary diagnosis was present in 92
patients (STEMI group); 100 patients had other acute cardiac
disease (non-ACS group) e.g. arrhythmias, heart failure, and
pulmonary embolism etc.
There were no statistically significant differences in base-
line demographic data or in cardiovascular risk factors
between groups except the known history of coronary artery
disease (CAD) and heart failure (Table 1). Mean serum
creatinine levels did not differ either.
Hyperphosphatemia at admission was more frequently
present in the non-ACS group, whereas hypophosphatemia
at admission was more frequent in STEMI patients (Fig. 1).
The dynamics of Pi in both groups are shown in Fig. 2. There
was no statistically significant difference in phosphatemia
after 6 h. Phosphatemia was significantly lower in STEMI
group 12 h after admission.19
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STEMI group – patients with ST segment elevation acute
myocardial infarction; non-ACS group – patients without
acute coronary syndrome. 
Fig. 1 – Phosphatemia at hospital admission.
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 p < 0.001 (difference between the groups at admission);
 p = 0.005 (difference between the groups after 12 hours);
STEMI group – patients with ST segment elevation acute
myocardial infarction; non-ACS group – patients without
acute coronary syndrome.
Fig. 2 – Time course of phosphatemia.
hypophosphatemia.In all hypophosphatemic STEMI patients, serum Pi normal-
ized itself within the first 6 h (increase of Pi by 0.1670.29
mmol/l)—Fig. 3.
There were no statistically significant differences in calcium,
potassium and magnesium level at admission in both groups
(calcium 2.370.15mmol/l in the STEMI group vs. 2.370.16
mmol/l in the non-ACS group, potassium 4.170.5mmol/l in
the STEMI group vs. 4.470.8 mmol/l in the non-ACS group,
magnesium 0.970.3 mmol/l in the STEMI group vs. 0.970.1
mmol/l in the non-ACS group). We found no correlation between
admission phosphatemia and other laboratory parameters
(admission serum total calcium level in STEMI patients r¼0.04,
p¼0.7074, serum potassium level in STEMI patients r¼0.05,
p¼0.6185 and serum magnesium level in STEMI patients
r¼0.20, p¼0.0743). In STEMI group, admission phosphatemia
did not correlate with peak troponin I (in STEMI patients r¼0.08,
p¼0.4640).5. Discussion
The main finding of our study was that STEMI patients have
lower serum phosphate levels at admission than acute
cardiac patients without acute coronary syndrome (ACS). In
those STEMI patients with initial hypophosphatemia, serum
Pi levels normalized within hours without exogenous phos-
phate administration.
The cause of hypophosphatemia in patients with ACS
might be the acute stress response, which requires more
energy and causes redistribution of phosphate into intracel-
lular space, where Pi may be transformed into adenosine
triphosphate and bind into damaged cell membranes of
necrotic myocardial cells. It has been documented that
hypophosphatemia may be the consequence of elevated
serum catecholamine levels (endogenous or exogenous epi-
nephrine and norepinephrine) or metabolic acidosis, which
induces increased urinary loss of phosphate [2,15]. In the
present study, we measured neither serum catecholamines
nor arterial pH in a systematic way. Another limitation of our
study was that we did not measure ionized calcium, serum
vitamin D or parathormone levels.
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renal function. In our study, however, the incidence of renal
insufficiency did not differ between the groups. Serum
phosphate may also decline after aspirin administration.
Aspirin has a protective effect on myocardial high energy
phosphates during ischemia and reperfusion [13] and reduces
Pi indirectly through the development of respiratory alkalosis
[16,17] and glycolysis is stimulated with intracellular phos-
phate shift. As all our STEMI patients received aspirin before
baseline phosphate measurement, the effect of aspirin may
be one of the reasons why we found lower phosphatemia in
the STEMI group as compared to heterogenous group of non-
ACS patients but explains neither the differences inside the
STEMI group nor the dynamics of Pi changes.
Another potential cause of hypophosphatemia may be the
intravenous administration of glucose and insulin stimulat-
ing carbohydrate metabolism and causing intracellular phos-
phate transport together with glucose mostly into the liver
and skeletal muscle cells [15]. Nevertheless, neither the
admission phosphate level nor subsequent values were
influenced by this mechanism, because none of our patients
received glucose infusion during the study period.
To our knowledge, there are very few published data about
serum phosphatemia in the acute phase of myocardial
infarction, mostly from the era when mechanical reperfusion
(i.e. primary percutaneous intervention) had not been used
yet. Khetagurov et al. [14] studied serum levels of phosphorus
and calcium in patients with acute myocardial infarction
during the initial phase of hospitalization. Interestingly,
patients with the lowest Pi and low variance of Pi had a
better clinical outcome. Gould et al. [13] described a signifi-
cant decline of the serum phosphorus in the third and
fourth postinfarction day as compared to the control group.
Conversely, the difference between groups on the first hospi-
talization day was not significant. They concluded that the
serum phosphate was a sensitive indicator of myocardial
inferction.
Interestingly enough, serum Pi in all our admission hypo-
phosphatemic STEMI patients (21% patients) returned to
normal values within 6 h without exogenous phosphorus
administration. It has been shown that longer lasting hypo-
phosphatemia may lead to clinically relevant consequences,
e.g. heart, respiratory failure and arrhythmias [1,2,8]. Ogni-
bene et al. [18] found positive association between low
phosphate and bicarbonate levels and the occurrence of
ventricular tachycardia in myocardial infarction. Vaidyanathan
et al. [19] investigated phosphate levels in acute MI patients
and found the association between hypophosphatemia and left
ventricular dysfunction as well as 30-day mortality. On the
contrary, in our STEMI group, we did not demonstrate a
significant correlation between phosphatemia and peak serum
troponin I levels.
In critically ill patients, hypophosphatemia might be asso-
ciated with higher mortality but the evidence as to whether
correction of hypophosphatemia improves the outcome is
poor. There is a general agreement to reserve intravenous
correction of hypophosphatemia for patients with associated
symptoms or phosphate levels o0.32 mmol/l [2,20]. Zazzo
et al. [21] found a positive effect of hypophosphatemia
correction on cardiac output in surgical intensive carepatients. We may only speculate on the possible effect of
primary percutaneous coronary intervention on early serum
phosphorus normalization as all our patients were treated in
this way. Similarly, it cannot be inferred from our study,
whether early rapid phosphate administration might be of
any clinical benefit for selected acute MI patients with severe
hypophosphatemia.6. Conclusions
We conclude that patients with acute myocardial infarction
with ST segment elevation treated by primary percutaneous
coronary intervention have lower serum inorganic phosphate
levels at admission and more frequent transient hypopho-
sphatemia than acute cardiac care patients without acute
coronary syndrome. Further studies are needed to better
define the relationship between acute myocardial infarction
and serum phosphorus levels.Acknowledgements
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